Terns Pharmaceuticals, Inc. $TERN Shares Sold by UBS Group AG

UBS Group AG reduced its holdings in Terns Pharmaceuticals, Inc. (NASDAQ:TERN) by 66.5% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 325,968 shares of the company’s stock after selling 646,804 shares during the period. UBS Group AG owned approximately 0.36% of Terns Pharmaceuticals worth $13,169,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the business. GAMMA Investing LLC raised its holdings in Terns Pharmaceuticals by 762.4% in the 4th quarter. GAMMA Investing LLC now owns 871 shares of the company’s stock valued at $35,000 after acquiring an additional 770 shares during the last quarter. Engineers Gate Manager LP acquired a new position in shares of Terns Pharmaceuticals during the 2nd quarter worth approximately $41,000. Canada Pension Plan Investment Board acquired a new position in shares of Terns Pharmaceuticals during the 2nd quarter worth approximately $46,000. Dynamic Technology Lab Private Ltd purchased a new stake in shares of Terns Pharmaceuticals in the first quarter valued at approximately $51,000. Finally, Polymer Capital Management US LLC purchased a new stake in shares of Terns Pharmaceuticals in the third quarter valued at approximately $76,000. 98.26% of the stock is currently owned by institutional investors and hedge funds.

Terns Pharmaceuticals Stock Performance

TERN opened at $52.95 on Friday. The stock has a market capitalization of $6.12 billion, a PE ratio of -51.41 and a beta of -0.37. Terns Pharmaceuticals, Inc. has a one year low of $2.65 and a one year high of $53.19. The business’s 50 day moving average price is $50.82 and its 200 day moving average price is $39.48.

Terns Pharmaceuticals (NASDAQ:TERN) last posted its earnings results on Monday, March 30th. The company reported ($0.24) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.30) by $0.06. As a group, equities research analysts forecast that Terns Pharmaceuticals, Inc. will post -1.22 earnings per share for the current fiscal year.

Insider Transactions at Terns Pharmaceuticals

In other Terns Pharmaceuticals news, insider Emil Kuriakose sold 942 shares of the company’s stock in a transaction dated Wednesday, April 1st. The shares were sold at an average price of $52.75, for a total value of $49,690.50. Following the transaction, the insider owned 105,673 shares of the company’s stock, valued at $5,574,250.75. This represents a 0.88% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, CEO Amy L. Burroughs sold 14,583 shares of the stock in a transaction dated Monday, March 16th. The stock was sold at an average price of $46.71, for a total transaction of $681,171.93. Following the transaction, the chief executive officer directly owned 288,976 shares of the company’s stock, valued at approximately $13,498,068.96. This trade represents a 4.80% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 30,108 shares of company stock valued at $1,302,370 over the last three months. Corporate insiders own 1.50% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities analysts recently commented on the company. TD Cowen downgraded Terns Pharmaceuticals from a “buy” rating to a “hold” rating and set a $53.00 price objective on the stock. in a research report on Thursday, March 26th. Citizens Jmp cut Terns Pharmaceuticals from a “market outperform” rating to a “hold” rating in a report on Thursday, March 26th. Barclays reaffirmed an “equal weight” rating and issued a $53.00 target price (down from $56.00) on shares of Terns Pharmaceuticals in a research note on Monday, March 30th. BMO Capital Markets cut shares of Terns Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Thursday, March 26th. Finally, HC Wainwright reissued a “neutral” rating and issued a $53.00 price objective (down from $60.00) on shares of Terns Pharmaceuticals in a report on Wednesday, March 25th. One equities research analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating, ten have given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, Terns Pharmaceuticals has an average rating of “Hold” and an average price target of $55.14.

About Terns Pharmaceuticals

Terns Pharmaceuticals, Inc is a clinical‐stage biopharmaceutical company focused on developing oral small‐molecule therapies for the treatment of chronic liver diseases and other serious conditions. The company’s research and development efforts center on novel mechanisms of action designed to address the underlying causes of progressive liver disorders, including inflammation, fibrosis and metabolic dysregulation. By advancing targeted compounds that can be administered orally, Terns aims to offer patients more convenient and effective treatment options compared to injectable or biologic therapies.

The company’s pipeline features several candidates in various stages of preclinical and clinical evaluation.